Inhibikase Therapeutics appoints David McIntyre as CFO as Garth Lees-Rolfe resigns

Inhibikase Therapeutics, Inc.

Garth Lees-Rolfe resigned as CFO effective April 11, 2025; not due to any dispute with the Company.
David McIntyre appointed CFO effective April 14, 2025; previously CFO of Anthos Therapeutics and partner at Apple Tree Partners.
McIntyre receives $485,000 base salary, 45% target bonus, and 3,142,967 stock options.
Lees-Rolfe to consult through Aug 15, 2025 at $33,333/month; options continue vesting.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David McIntyre

Chief Financial Officer

IKT · Inhibikase Therapeutics, Inc.

Effective: 2025-04-14
Filed: April 14, 2025, 7:59 PM ET

Effective April 14, 2025, the Board appointed David McIntyre as Chief Financial Officer, principal financial officer and principal accounting officer of the Company (the “Appointment”).

Departed

Garth Lees-Rolfe

Chief Financial Officer

IKT · Inhibikase Therapeutics, Inc.

Effective: 2025-04-11
Successor: David McIntyre
Filed: April 14, 2025, 7:59 PM ET

Effective April 11, 2025, Garth Lees-Rolfe resigned as Chief Financial Officer, principal financial officer and principal accounting officer of Inhibikase Therapeutics, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

David McIntyre was appointed as Chief Financial Officer at Inhibikase Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective April 14, 2025, the Board appointed David McIntyre as Chief Financial Officer, principal financial officer and principal accounting officer of the Company (the “Appointment”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Garth Lees-Rolfe resigned as Chief Financial Officer at Inhibikase Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Effective April 11, 2025, Garth Lees-Rolfe resigned as Chief Financial Officer, principal financial officer and principal accounting officer of Inhibikase Therapeutics, Inc. (the “Company”).

View on SEC.gov

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-079656

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.